Back to Trials
NCT06380114NARecruitingAccepts Healthy Volunteers

Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination

University of Rochester

Start Date

11/4/2024

Completion Date

5/1/2028

Summary

Each year in the U.S., ≥20,000 women and 14,000 men are affected by HPV-related cancers, including cervical and oropharyngeal cancer. However, in 2020, only 59% of U.S. adolescents aged 13-17 were up-to-date for HPV vaccination, and rates for 11-12 year olds, the primary target age group for HPV vaccination (when the immune reaction is better and before exposure to HPV infection), are even lower. Standing orders (written protocols that authorize designated members of the healthcare team to vaccinate without first obtaining a patient-specific physician order) have been shown to work in inpatient settings and for adults, but have not been evaluated for HPV vaccine, which some parents consider controversial. Also, the ways in which organizational readiness for change (resources, motivation, staff attributes, leadership support and culture) moderate the effect of standing orders has not been studied. A physician's recommendation is correlated with HPV vaccine acceptance, and the investigators have developed a successful online, interactive, communication education program that will be adapted to train nurses and staff in addition to physicians. The investigators propose testing standing orders for HPV vaccine in an Accountable Care Organization (ACO) in Western New York, and assessing which provider and practice factors moderate the effect of standing orders. Advantages of this setting include a diverse group of rural, urban and suburban practices, and the ACO provides data infrastructure and analytics that allow practices to evaluate vaccination rates in real time. Using a 2-arm cluster randomized trial (n=40 practices), the investigators will assess the effectiveness of standing orders (SO) + HPV communication education (intervention arm) relative to HPV communication education alone (control arm) on HPV vaccination for 9-17 year-olds.

Eligibility Criteria

Age Range: 9 years to 17 years

Inclusion Criteria: * active patient in AHP practice Exclusion Criteria: * patient belonging to a practice with \>80% UTD baseline HPV vaccination rate for ages 13-17 * patient belonging to a practice with \<20 11-12 year-olds eligible for an HPV dose

Interventions

BEHAVIORAL

Communication

BEHAVIORAL

Standing Orders

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Hpv

Locations

University of Rochester Medical Center (URMC)

Rochester, New York 14642

United States